Pages

▼
Thursday, March 31, 2011

RXi Pharmaceuticals Invites Biotech Speculators

›
Times have never been tougher if you are a preclinical-stage biotechnology company with a high demand for cash to support operations. At l...
3 comments:
Tuesday, March 29, 2011

Alnylam and Big Pharma: Tekmira Caught in a Tangled Web of Interests

›
( Notice : The following account is a largely hypothetical explanation of what is underlying Alnylam's current troubles) The last time A...
8 comments:
Wednesday, March 23, 2011

Alnylam Now Sued by University of Utah Over 3’ Overhang Inventorship

›
Not a day goes by without a lawsuit involving Alnylam. This time it would seem unjustly so. The company disclosed in a regulatory filing...
4 comments:
Monday, March 21, 2011

Quark RNAi Therapeutics Drug Candidate for Diabetic Macular Edema Effective, but Changing Competitive Landscape Weighs

›
A lot has changed in the treatment of diabetic macular edema (DME) since Quark sub-licensed its AtuRNAi compound to Pfizer in 2006. Most not...
4 comments:
Thursday, March 17, 2011

Tekmira Tells Alnylam ‘Enough is Enough’

›
The reason why I have been a strong supporter of Tekmira is because I give them the scientific credit for developing the most valuable syste...
21 comments:
Friday, March 11, 2011

Are Quark Pharmaceuticals’ Ocular Programs About to Meet Expected Fate?

›
Recent entries to the ocular clinical trials by Pfizer listed in ClinicalTrials.gov (see here and here ) suggest that its first-generation ...
5 comments:
Sunday, March 6, 2011

Marina Biotech Finds Success with Local Bladder Cancer Approach

›
Marina Biotech this week reported pre-clinical data supporting the use of local, intravesicular siRNA delivery for the treatment of nonmusc...
3 comments: